These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 24373071)

  • 1. How to optimize current therapy of HCV genotype 1 infection with boceprevir.
    Bourlière M; Adhoute X; Wendt A; Ansaldi C; Oules V; Castellani P
    Liver Int; 2014 Feb; 34 Suppl 1():4-10. PubMed ID: 24373071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
    Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F;
    J Clin Virol; 2015 Dec; 73():32-35. PubMed ID: 26528903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
    Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
    Butt AA; Kanwal F
    Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of HCV transplant patients with triple therapy.
    Coilly A; Roche B; Duclos-Vallée JC; Samuel D
    Liver Int; 2014 Feb; 34 Suppl 1():46-52. PubMed ID: 24373078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.
    Cammà C; Petta S; Cabibbo G; Ruggeri M; Enea M; Bruno R; Capursi V; Gasbarrini A; Alberti A; Craxì A;
    J Hepatol; 2013 Oct; 59(4):658-66. PubMed ID: 23707373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future perspectives: towards interferon-free regimens for HCV.
    Gane E
    Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal treatment with boceprevir for chronic HCV infection.
    Maasoumy B; Manns MP
    Liver Int; 2013 Feb; 33 Suppl 1():14-22. PubMed ID: 23286841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing treatment in HIV/HCV coinfection.
    Puoti M; Rossotti R; Travi G; Panzeri C; Morreale M; Chiari E; Cocca G; Orso M; Moioli MC
    Dig Liver Dis; 2013 Sep; 45 Suppl 5():S355-62. PubMed ID: 24091116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
    Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
    J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir.
    Benito JM; Sánchez-Parra C; Maida I; Aguilera A; Rallón NI; Rick F; Labarga P; Fernández-Montero JV; Barreiro P; Soriano V
    Antivir Ther; 2013; 18(5):709-15. PubMed ID: 23645335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of hepatitis C: current status and perspectives].
    Pol S; Corouge M
    Rev Prat; 2014 May; 64(5):605-12. PubMed ID: 24923038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hepatitis C virus: 25 years-old, the end?].
    Pol S
    Med Sci (Paris); 2013 Nov; 29(11):998-1003. PubMed ID: 24280503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
    Belperio PS; Hwang EW; Thomas IC; Mole LA; Cheung RC; Backus LI
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1021-7. PubMed ID: 23524130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].
    Zuckerman E; Safadi R; Oren R; Shibolet O; Baruch Y; Bruck R; Lurei Y; Kaspa RT; Abu-Mouch S; Shouval D; Ben-Ari Z;
    Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.
    Marks KM; Jacobson IM
    Antivir Ther; 2012; 17(6 Pt B):1119-31. PubMed ID: 23188750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boceprevir, an NS3 protease inhibitor of HCV.
    Berman K; Kwo PY
    Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future of hepatitis C therapy: development of direct-acting antivirals.
    Dore GJ; Matthews GV; Rockstroh J
    Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C].
    Sarrazin C; Berg T; Cornberg M; Dollinger M; Ferenci P; Hinrichsen H; Klinker H; Kraus M; Manns M; Mauss S; Peck-Radosavljevic M; Schmidt H; Spengler U; Wedemeyer H; Wirth S; Zeuzem S
    Z Gastroenterol; 2012 Jan; 50(1):57-72. PubMed ID: 22222799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.